The oral JAK inhibitor tofacitinib has been linked to pulmonary arterial hypertension in a patient seen at a Sydney clinic. In a letter in the Journal of Clinical Rheumatology, a team of cardiologists and rheumatologists from Sydney Adventist Hospital and Macquarie University present the case of a 32 year old female with a provisional diagnosis ...
JAK inhibitor linked to PAH in case study
By Nicola Garrett
13 Nov 2018